Genentech INC

lobbying client · lobbying firm

Genentech INC's federal footprint — reported lobbying spend and, where matched, federal money received. Figures are as reported to the U.S. Senate (LDA) and USAspending.

Lobbying from Senate LDA

Reported lobbying (spent)$46,040,000

Years coveredFY2022–FY2026

Reported lobbying billed / handled $37,800,000

Firm activeFY2022–FY2025

Reported country: 🇺🇸 United States

Lobbying over time

Reported lobbying for Genentech INC per filing year
FY	Lobbying spend (as client)	Lobbying billed / handled (as firm)
2022	$10,870,000	$8,770,000
2023	$11,530,000	$9,500,000
2024	$11,120,000	$9,110,000
2025	$12,460,000	$10,420,000
2026	$60,000	—

Two figures: what Genentech INC reported spending on its own lobbying (as a client) and what it billed or handled for the clients it represents (as a firm — revenue, not its own spend). For a self-filer these overlap.

Firms hired

Tarplin, Downs & Young, LLC $1,080,000 · 18 filings
Ogr $1,030,000 · 16 filings
Todd Strategy Group $1,030,000 · 17 filings
Tiber Creek Health Strategies, INC. $960,000 · 16 filings
Marshall & Popp, LLC $960,000 · 16 filings
Harbinger Strategies, LLC $910,000 · 18 filings
Akin Gump Strauss Hauer & Feld $800,000 · 16 filings
Cornerstone Government Affairs, INC. $800,000 · 16 filings
King & Spalding LLP $440,000 · 16 filings
Crossroads Strategies, LLC $200,000 · 4 filings

Registrants that filed lobbying on behalf of Genentech INC.

Clients represented

Self-filed — Genentech INC registers and lobbies on its own behalf, with no separate outside clients.

Issues

Issue area	Lobbied	Worked
Health Issues	125	16
Medicare/Medicaid	66	16
Budget/Appropriations	57	16
Pharmacy	49	16
Copyright/Patent/Trademark	43	16
Trade (domestic/foreign)	40	16
Taxation/Internal Revenue Code	38	16
Immigration	16	16
Manufacturing	16	16
Medical/Disease Research/Clinical Labs	16	16

Issue areas across Genentech INC's filings, by activity count — as the client (Lobbied) and as the registrant/firm (Worked). Linked areas open the CivicGate issue page.

What they lobbied on

Reported activity from Senate LDA

FY2026 Taxation/Internal Revenue Code as client

Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income). P.L. 119-21.
FY2026 Health Issues as client

Issues related to drug pricing. Issues related to the 340B Drug Discount Program.
FY2025 Health Issues as client

Advocacy related to access to healthcare.
FY2025 Taxation/Internal Revenue Code as client

Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income).
FY2025 Health Issues as client

Issues related to drug pricing. Issues related to the 340B Drug Discount Program.
FY2025 Medicare/Medicaid as client

MINI Act, IRA, Medicare & Medicaid payment and coverage issues, CMMI, orphan drugs
FY2025 Health Issues as client

IRA, drug pricing and access, transparency, drug pricing in federal programs, PAPH reauthorization, supply chain
FY2025 Budget/Appropriations as client

Federal budget issues

Show 52 more activities

FY2025 Health Issues as client

Issues related to public health preparedness. Issues related to access to drugs for minority communities. Issues related to healthcare education and screening. Issues related to 340B Reform. Issues related to PBM Reform.
FY2025 Pharmacy as client

Issues related to prescription drug value, including H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; and implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including H.R. 2882, FY2024 Further Consolidated Appropriations Act. Issues related to the 340B program.

H.R. 1492 H.R. 2882
FY2025 Copyright/Patent/Trademark as client

Issues related to tariff and trade policy.
FY2025 Trade (domestic/foreign) as client

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

H.Con.Res. 14 S.Con.Res. 7
FY2025 Pharmacy as client

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

H.R. 1492
FY2025 Copyright/Patent/Trademark as client

Issues related to tariff and trade policy.
FY2025 Trade (domestic/foreign) as client

Issues related to budget reconciliation, including H.Con.Res. 14 and S.Con.Res. 7.

H.Con.Res. 14 S.Con.Res. 7
FY2025 Health Issues as client

Advocacy related to access to healthcare.
FY2025 Taxation/Internal Revenue Code as client

Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income).
FY2025 Health Issues as client

Issues related to drug pricing. Issues related to the 340B Drug Discount Program.
FY2025 Budget/Appropriations as client

Appropriations relating to pandemic influenza.
FY2025 Health Issues as client

Appropriations relating to pandemic influenza.
FY2025 Health Issues as client

Issues related to drug pricing and patient access
FY2025 Budget/Appropriations as client

Appropriations relating to influenza.
FY2025 Health Issues as client

Appropriations relating to influenza.
FY2025 Budget/Appropriations as client

Appropriations relating to influenza.
FY2025 Health Issues as client

Appropriations relating to influenza.
FY2025 Health Issues as client

Issues related to public health preparedness; Issues related to access to drugs for minority communities; Issues related to healthcare education and screening.
FY2025 Medicare/Medicaid as client

Medicare and Medicaid payment issues. 340B. Implementation of Inflation Reduction Act of 2022.
FY2025 Pharmacy as client

Prescription drug payment reform. Supply chain. Strategic National Stockpile.
FY2025 Taxation/Internal Revenue Code as client

Issues related to corporate taxation including corporate rate; deductibility of research and development expenses; and international taxation (Foreign Derived Intangible Income). P.L. 119-21.
FY2025 Health Issues as client

Issues related to drug pricing. Issues related to the 340B Drug Discount Program.
FY2025 Copyright/Patent/Trademark self-filed

Intellectual property and process patent issues Patent litigation reforms PTAB and IPR processes Section 101 Reform Domestic and international compulsory licensing issues March-in Rights
FY2025 Budget/Appropriations self-filed

Issues related to FDA and HHS program funding for the FY25 Labor, HHS, Education and Related Agencies, and FY25 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicineS Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance Deficit reduction, reconciliation
FY2025 Health Issues self-filed

Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. Issues related to healthcare legislation Patient access to Part B medicines Issues related to health equity, diversity, and inclusion in clinical trials Issues related to advanced development and procurement of medical countermeasures (MCMs) Issues related to patient assistance and access Issues relating to privacy and securing the data of and personal information of consumers Issues relating to medical research data Issues relating to screening and diagnostics Issues related to public health preparedness and response Issues related to awareness about diabetic eye diseases in minority populations Issues related to public health preparedness. Issues related to access to drugs for minority communities Issues related to healthcare education and screening
FY2025 Medicare/Medicaid self-filed

Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars Issues related to CMMI
FY2025 Taxation/Internal Revenue Code self-filed

Issues related to R&D tax deductions and expense amortization Issues related to international taxation, including foreign-derived intangible income and interest deductions Issues related to supply chain incentives
FY2025 Trade (domestic/foreign) self-filed

Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver Issues related to compulsory licensing of foreign patents Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
FY2025 Medical/Disease Research/Clinical Labs self-filed

Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development Issues related to research and product development Issues related to drug development including PDUFA
FY2025 Pharmacy self-filed

Drug pricing issues Prescription Drug User Fee Act reauthorization Issues related to prescription drug value Issues related to the 340B Drug Discount Program
FY2025 Manufacturing self-filed

Issues related to pharmaceutical supply chains Issues related to reporting on location of origin of pharmaceutical products Issues related to drug shortages Issues related to pharmaceutical manufacturing
FY2025 Immigration self-filed

Issues relating to limits and restrictions on the immigration of high skilled workers Issues relating to the immigration of medical researchers
FY2025 Health Issues as client

Issues related to the 340b program - Public Health Service Act (P.L. 78-410); Issues related to PBM reform.
FY2025 Pharmacy self-filed

Drug pricing issues Prescription Drug User Fee Act reauthorization Issues related to prescription drug value Issues related to the 340B Drug Discount Program
FY2025 Budget/Appropriations self-filed

Issues related to FDA and HHS program funding for the FY25 Labor, HHS, Education and Related Agencies, and FY25 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Strategic National Stockpile (SNS) Funding and Oversight Funding for FDA e-labeling rule implementation Patient access to Part B medicineS Issues related to 340B program oversight Support for increased investments to address antimicrobial resistance Deficit reduction, reconciliation
FY2025 Copyright/Patent/Trademark self-filed

Intellectual property and process patent issues Patent litigation reforms PTAB and IPR processes Section 101 Reform Domestic and international compulsory licensing issues March-in Rights
FY2025 Health Issues self-filed

Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. Issues related to healthcare legislation Patient access to Part B medicines Issues related to health equity, diversity, and inclusion in clinical trials Issues related to advanced development and procurement of medical countermeasures (MCMs) Issues related to patient assistance and access Issues relating to privacy and securing the data of and personal information of consumers Issues relating to medical research data Issues relating to screening and diagnostics Issues related to public health preparedness and response Issues related to awareness about diabetic eye diseases in minority populations Issues related to public health preparedness. Issues related to access to drugs for minority communities Issues related to healthcare education and screening
FY2025 Medicare/Medicaid self-filed

Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars Issues related to CMMI
FY2025 Taxation/Internal Revenue Code self-filed

Issues related to R&D tax deductions and expense amortization Issues related to international taxation, including foreign-derived intangible income and interest deductions Issues related to supply chain incentives
FY2025 Trade (domestic/foreign) self-filed

Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver Issues related to compulsory licensing of foreign patents Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
FY2025 Medical/Disease Research/Clinical Labs self-filed

Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development Issues related to research and product development Issues related to drug development including PDUFA
FY2025 Manufacturing self-filed

Issues related to pharmaceutical supply chains Issues related to reporting on location of origin of pharmaceutical products Issues related to drug shortages Issues related to pharmaceutical manufacturing
FY2025 Immigration self-filed

Issues relating to limits and restrictions on the immigration of high skilled workers Issues relating to the immigration of medical researchers
FY2025 Medicare/Medicaid as client

MINI Act, IRA, Medicare & Medicaid payment and coverage issues, CMMI, orphan drugs
FY2025 Health Issues as client

IRA, drug pricing and access, transparency, 340B, PAPH reauthorization, supply chain
FY2025 Budget/Appropriations as client

Federal budget issues
FY2025 Health Issues as client

Drug pricing and patient access issues
FY2025 Health Issues as client

Issues related to public health preparedness; Issues related to access to drugs for minority communities; Issues related to healthcare education and screening.
FY2025 Health Issues as client

Issues related to public health preparedness. Issues related to access to drugs for minority communities. Issues related to healthcare education and screening. Issues related to 340B Reform. Issues related to PBM Reform.
FY2025 Health Issues as client

Issues related to public health preparedness; issues related to access to medicines for minority communities; issues related to healthcare education and screening.
FY2025 Pharmacy as client

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.

H.R. 1492
FY2025 Copyright/Patent/Trademark as client

Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.

S. 1040 S. 1041

The specific issues and bills Genentech INC reported lobbying on, newest first. Bill references that CivicGate tracks link to the bill; others are shown as reported.